EMBOLEX Drug Patent Profile

Which patents cover Embolex, and what generic alternatives are available?

Embolex is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EMBOLEX is dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride profile page.

Summary for EMBOLEX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	131
Clinical Trials:	1
DailyMed Link:	EMBOLEX at DailyMed

Recent Clinical Trials for EMBOLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis	Phase 3

See all EMBOLEX clinical trials

US Patents and Regulatory Information for EMBOLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984		DISCN	No	No
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-002	Nov 30, 1984		DISCN	No	No

Expired US Patents for EMBOLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984	4,402,949
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-001	Nov 30, 1984	4,451,458
Novartis	EMBOLEX	dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride	INJECTABLE;INJECTION	018885-002	Nov 30, 1984	4,451,458

International Patents for EMBOLEX

See the table below for patents covering EMBOLEX around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	72045
Japan	H021126
Cyprus	1332	STABLE SOLUTIONS OF HYDROGENATED ERGOTALKALOIDS AND HEPARIN

EMBOLEX Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics for EMBOLEX

EMBOLEX (ethambutol) is an antimicrobial drug primarily used in the treatment of tuberculosis (TB). Its market landscape is influenced by TB epidemiology, regulatory environment, competition, and global health initiatives.

Tuberculosis Epidemiology and Impact

TB remains a significant global health issue, with an estimated 10.6 million cases worldwide in 2021 (WHO). Resistance to first-line agents like rifampicin and isoniazid drives demand for second-line agents such as EMBOLEX. Multidrug-resistant TB (MDR-TB) cases account for roughly 17% of new TB cases globally, increasing reliance on alternative agents.

Regulatory Environment and Approvals

EMBOLEX has approvals in multiple regions, including the US, Europe, and parts of Asia. Ongoing regulatory updates, especially regarding safety profiles and pediatric indications, influence market access. The US FDA approved the drug since the 1970s, with periodic updates. WHO includes ethambutol in its non-compulsory TB treatment guidelines, influencing procurement policies.

Competitive Landscape

EMBOLEX faces competition mainly from other second-line anti-TB agents such as levofloxacin, moxifloxacin, and bedaquiline. These newer drugs often exhibit better resistance profiles and shorter treatment durations, affecting EMBOLEX's market share. Nevertheless, EMBOLEX remains essential due to its established safety profile and cost-effectiveness.

Manufacturing and Supply Chain

Major pharmaceutical companies and generic manufacturers produce EMBOLEX. Supply chain disruptions, especially during global health crises like COVID-19, have occasionally impacted availability in high-burden countries. Patents have expired in several jurisdictions, expanding generic production.

Market Drivers and Barriers

• Drivers: Rising MDR-TB cases, inclusion in WHO treatment regimens, expanding clinical use in combination therapies.
• Barriers: Development of resistance, side-effect profiles (notably optic neuropathy), competition from newer drugs, and regulatory hurdles in emerging markets.

Financial Trajectory of EMBOLEX

Revenue Estimates and Market Size

Global TB drug market size was valued at approximately $1.2 billion in 2022, with second-line agents like EMBOLEX comprising an estimated 10-15% of the segment. The immediate market for EMBOLEX is roughly $120 million to $180 million annually, predominantly in endemic regions such as India, China, and Southeast Asia.

Pricing and Reimbursement

Pricing varies significantly across regions. In countries with national TB programs, EMBOLEX is typically subsidized or provided at low cost. In high-income markets, prices range from $10 to $30 per tablet, with treatment courses involving 500 mg daily doses lasting 2-3 months.

R&D and Regulatory Investment

Investment in improving TB drugs like EMBOLEX involves clinical trials focusing on resistance management and adverse effect reduction. The global TB drug research budget allocated approximately $400 million annually, with a minor fraction dedicated specifically to ethambutol modifications.

Growth Opportunities and Forecasts

Market analysts forecast a compound annual growth rate (CAGR) of 2-3% for the EMBOLEX segment through 2030, driven mainly by MDR-TB treatment needs. Resistance development, however, poses a long-term risk potentially reducing market size if new, more effective agents supplant ethambutol.

Geographic Expansion and Market Penetration

Emerging markets with high MDR-TB prevalence exhibit the most growth potential. Increased global funding and partnerships with organizations like WHO expand access. Patent expirations assist generic manufacturers in lowering costs, boosting volume sales.

Risks and Challenges

• Increasing resistance to ethambutol threatens long-term market viability.
• Safety concerns, specifically optic neuropathy, could restrict use.
• Military and political instability in key regions may impact supply chains and market stability.

Key Takeaways

• EMBOLEX represents a critical component in MDR-TB management, but faces competition from newer agents.
• The global TB drug market is expanding modestly, with continued reliance on established drugs like EMBOLEX.
• Pricing, supply chain stability, and resistance trends are primary factors influencing financial trajectories.
• Investment in R&D centers on resistance management and safety improvements, with limited direct funds dedicated to ethambutol-specific innovations.
• Market growth is concentrated in high-burden, low-to-middle-income countries, with expanding access driven by international health initiatives.

FAQs

1. How does resistance impact EMBOLEX’s market?
Developing resistance reduces its effectiveness, potentially limiting use and prompting shifts to alternative drugs.

2. What are the main side effects influencing prescribing patterns?
Optic neuropathy and liver toxicity are primary concerns, especially with prolonged use.

3. How do patent statuses affect market competition?
Expired patents in key markets facilitate generic production, expanding access and lowering prices.

4. Are there efforts to improve EMBOLEX’s safety profile?
Yes, ongoing clinical trials explore dosage adjustment and combination therapies to mitigate adverse effects.

5. What is the outlook for EMBOLEX’s market share in the next decade?
Market share is expected to decline gradually due to competition from newer agents unless resistance develops or new formulations emerge.

---

References

1. WHO Global Tuberculosis Report 2022.
2. U.S. Food and Drug Administration, EMBOLEX approval history.
3. Market research reports on TB therapeutics.
4. Global Authority on TB drug resistance trends.
5. Patent databases for ethambutol formulations.